NCT02308943: Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors |
|
|
| Not yet recruiting | 1 | 90 | US | Cabozantinib S-malate, BMS-907351, Cometriq, XL184, Nivolumab, anti-PD-1 human monoclonal antibody MDX-1106, BMS-936558, MDX-1106, ONO-4538, Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Laboratory Biomarker Analysis | National Cancer Institute (NCI) | Adult Solid Neoplasm, Malignant Reproductive System Neoplasm, Malignant Urinary System Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Progressive Neoplastic Disease, Recurrent Bladder Carcinoma, Recurrent Urethra Carcinoma, Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter, Regional Urothelial Carcinoma of the Renal Pelvis and Ureter, Stage III Bladder Urothelial Carcinoma, Stage III Urethral Cancer, Stage IV Bladder Urothelial Carcinoma, Stage IV Urethral Cancer, Urethral Urothelial Carcinoma | 08/17 | | | |
